Compounds > rhenium
Page last updated: 2024-08-22

rhenium and ER-Negative PR-Negative HER2-Negative Breast Cancer

rhenium has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Antomarchi, J; Cohen, C; Collery, P; Guigonis, JM; Krossa, I; Lagadec, P; Lucio, M; Schmid-Alliana, A; Schmid-Antomarchi, H; Scimeca, JC; Varlet, D1
Azemati, S; Banerjee, HN; Barfield, A; Chen, C; Ghimire, S; Giri, D; Golen, JA; Hinton, TV; Ho, DM; Krause, JA; Mandal, SK; McCarthy, P; Odebode, T; Olczak, P; Parnell, S; Powell, BV; Pramanik, SK; Rheingold, AL; Shaw, R; Stevenson, M; Tadesse, S; Wachira, JM; Weber, DJ; Wilder, PT; Winstead, A; Zavalij, PY; Zhang, Y1
Collery, P; Desmaele, D; Harikrishnan, A; Veena, V1

Other Studies

3 other study(ies) available for rhenium and ER-Negative PR-Negative HER2-Negative Breast Cancer

ArticleYear
Relationship between the oxidative status and the tumor growth in transplanted triple-negative 4T1 breast tumor mice after oral administration of rhenium(I)-diselenoether.
    Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS), 2022, Volume: 71

    Topics: Administration, Oral; Advanced Oxidation Protein Products; Animals; Biomarkers; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Mice; Mice, Inbred BALB C; Oxidative Stress; Rhenium; Triple Negative Breast Neoplasms; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A

2022
Unprecedented anticancer activities of organorhenium sulfonato and carboxylato complexes against hormone-dependent MCF-7 and hormone-independent triple-negative MDA-MB-231 breast cancer cells.
    Molecular and cellular biochemistry, 2018, Volume: 441, Issue:1-2

    Topics: Antineoplastic Agents; Coordination Complexes; Female; Humans; MCF-7 Cells; Organometallic Compounds; Rhenium; Triple Negative Breast Neoplasms

2018
The rhenium(I)-diselenoether anticancer drug targets ROS, TGF-β1, VEGF-A, and IGF-1 in an in vitro experimental model of triple-negative breast cancers.
    Investigational new drugs, 2019, Volume: 37, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Coordination Complexes; Female; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Insulin-Like Growth Factor I; Models, Theoretical; Reactive Oxygen Species; Rhenium; Selenium Compounds; Transforming Growth Factor beta1; Triple Negative Breast Neoplasms; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A

2019